Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Biochemical Engineering >  Inhibitors >  Epigenetics >  HDAC inhibitors >  Belinostat (PXD101)

Belinostat (PXD101)

Basic information Safety Supplier Related

Belinostat (PXD101) Basic information

Product Name:
Belinostat (PXD101)
Synonyms:
  • PXD101, Beliomsta
  • BELINOSTAT (PXD101);PXD101
  • PXD101
  • N-HYDROXY-3-[3-[(PHENYLAMINO)SULFONYL]PHENYL]-2-PROPENAMIDE
  • N-HYDROXY-3-(3-PHENYLSULFAMOYLPHENYL)ACRYLAMIDE
  • Belinostat
  • Belinostat(PXD101)
  • 2-PropenaMide, N-hydroxy-3-[3-[(phenylaMino)sulfonyl]phenyl]-
CAS:
414864-00-9
MF:
C15H14N2O4S
MW:
318.35
Product Categories:
  • Inhibitors
  • API
  • Inhibitor
Mol File:
414864-00-9.mol
More
Less

Belinostat (PXD101) Chemical Properties

Melting point:
142 - 145°C
Density 
1.427±0.06 g/cm3(Predicted)
storage temp. 
Amber Vial, Refrigerator, Under inert atmosphere
solubility 
DMSO (Slightly), Methanol (Slightly)
form 
Solid
pka
8.31±0.10(Predicted)
color 
Off-White to Pale Orange
Stability:
Light Sensitive
More
Less

Safety Information

HS Code 
29350090
More
Less

Belinostat (PXD101) Usage And Synthesis

Description

Belinostat is a drug which was developed by Spectrum Pharmaceuticals and is currently marketed by Onxeo as Beleodaq®. The drug, which received fast track designation by the United States Food and Drug Administration (US FDA) and was approved for the treatment of hematological malignancies and solid tumors associated with peripheral T-cell lymphoma (PTCL) in 2014, is a histone deacetylase (HDAC) inhibitor and is the third such treatment to receive accelerated approval for PTCL, the others being vorinostat (Zolinza®) and pralatrexate (Folotyn®). Although belinostat was not yet approved in Europe as of August 2014, the compound exhibits a safety profile considered to be acceptable for HDAC inhibitors–less than 25% of patients reported adverse effects and these most frequently were nausea, fatigue, pyrexia, anemia, and emesis.

Uses

Belinostat is a novel histone deacetylase 3 selective inhibitor, which protects the β cells from cytokine-induced apoptosis.

Definition

ChEBI: A hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity.

Synthesis

Commercially available 3-bromobenzenesulfonyl chloride (41) was reacted with aniline in the presence of aqueous sodium carbonate to deliver sulfonamide 42 in 94% yield. Next, this aryl bromide was subjected to a Heck reaction involving ethyl acrylate to give rise to cinnamate ester 43, which was immediately saponified under basic conditions and acidic workup to furnish the corresponding acid 44. This acid was activated as the corresponding acid chloride prior to subjection to hydroxylamine under basic conditions to form the hydroxamic acid, which was then recrystallized from an 8:1 ethanol/water mixture in the presence of a catalytic amount of sodium bicarbonate to furnish crystalline belinostat (VI) in 87% overall yield from acid 44.

target

pan-HDAC

Belinostat (PXD101)Supplier

Shanghai Boyle Chemical Co., Ltd.
Tel
Email
sales@boylechem.com
J & K SCIENTIFIC LTD.
Tel
010-82848833 400-666-7788
Email
jkinfo@jkchemical.com
Chembest Research Laboratories Limited
Tel
+86-21-20908456
Email
sales@BioChemBest.com
Jinan Trio PharmaTech Co., Ltd.
Tel
+86 (531) 88811783
Email
sales@trio-pharmatech.com (International market)
Hunan Hui Bai Shi Biotechnology Co., Ltd.
Tel
0731-85526065 13308475853
Email
ivy@hnhbsj.com